ATE355380T1 - Methode zur selektiven inaktivierung der viralen replication - Google Patents

Methode zur selektiven inaktivierung der viralen replication

Info

Publication number
ATE355380T1
ATE355380T1 AT94912387T AT94912387T ATE355380T1 AT E355380 T1 ATE355380 T1 AT E355380T1 AT 94912387 T AT94912387 T AT 94912387T AT 94912387 T AT94912387 T AT 94912387T AT E355380 T1 ATE355380 T1 AT E355380T1
Authority
AT
Austria
Prior art keywords
virus
viral replication
rna
agent
selective inactivation
Prior art date
Application number
AT94912387T
Other languages
English (en)
Inventor
Vincent J Miles
Michael B Mathews
Michael G Katze
Gary Witherell
Julia C Watson
Original Assignee
Rigel Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rigel Pharmaceuticals Inc filed Critical Rigel Pharmaceuticals Inc
Application granted granted Critical
Publication of ATE355380T1 publication Critical patent/ATE355380T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Analytical Chemistry (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
AT94912387T 1993-04-02 1994-04-01 Methode zur selektiven inaktivierung der viralen replication ATE355380T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4202493A 1993-04-02 1993-04-02

Publications (1)

Publication Number Publication Date
ATE355380T1 true ATE355380T1 (de) 2006-03-15

Family

ID=21919634

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94912387T ATE355380T1 (de) 1993-04-02 1994-04-01 Methode zur selektiven inaktivierung der viralen replication

Country Status (8)

Country Link
US (2) US5738985A (de)
EP (1) EP0693126B9 (de)
JP (2) JP3901726B2 (de)
AT (1) ATE355380T1 (de)
AU (1) AU6497694A (de)
CA (1) CA2159639A1 (de)
DE (1) DE69434931T2 (de)
WO (1) WO1994023041A2 (de)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6627610B1 (en) 1992-05-29 2003-09-30 Jeffrey Glenn Method for inhibition of viral morphogenesis
US5503973A (en) * 1992-05-29 1996-04-02 The Regents Of The University Of California Method for inhibition of viral morphogenesis
US6159939A (en) * 1995-06-23 2000-12-12 Glenn; Jeffrey Method for inhibition of viral morphogenesis
US6824976B1 (en) * 1993-04-02 2004-11-30 Rigel Pharmaceuticals, Inc. Method for selective inactivation of viral replication
JPH09504176A (ja) * 1993-10-25 1997-04-28 ライボジーン、インコーポレイテッド 抗真菌剤の選抜法
US5750394A (en) * 1994-05-20 1998-05-12 The Mount Sinai Medical Center Identification and use of antiviral compounds that inhibit interaction of host cell proteins and viral proteins required for viral replication
GB9420735D0 (en) * 1994-10-14 1994-11-30 Karobio Ab Reporter cell line
US6503703B1 (en) 1995-05-19 2003-01-07 Mount Sinai School Of Medicine Of New York University Identification and use of antiviral compounds that inhibit interaction of host cell proteins and viral proteins required for viral replication
AU742243B2 (en) * 1996-04-15 2001-12-20 Vanderbilt University Mammalian genes involved in viral infection and tumor suppression
CA2283379A1 (en) * 1997-03-05 1998-09-11 Michael G. Katze Novel screening methods to identify agents that selectively inhibit hepatitis c virus replication
US20020137890A1 (en) * 1997-03-31 2002-09-26 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP1029062A1 (de) * 1997-10-16 2000-08-23 Temple University of the Commonwealth System of Higher Education Inhibierung der replikation des menschlichen immunschwächevirus (hiv-1)
US6197502B1 (en) 1997-11-17 2001-03-06 Cytos Biotechnology Ag Expression cloning processes for the discovery characterization, and isolation of genes encoding polypeptides with a predetermined property
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
US7019195B1 (en) * 1998-05-26 2006-03-28 Syngenta Participations Ag Method for conferring resistance or tolerance aganist furovirus, potyvirus, tospovirus, and cucomovirus to plant cells
GB9820025D0 (en) * 1998-09-14 1998-11-04 Pfizer Ltd Assay
CA2280276A1 (en) * 1998-09-14 2000-03-14 Pfizer Inc. Assay for detecting modulators of serine/threonine phosphatase activity
US6562571B1 (en) * 1999-05-25 2003-05-13 University Of Rochester Human heme-regulated initiation factor 2-α kinase
US6448007B1 (en) * 1999-07-02 2002-09-10 Message Pharmaceuticals Functional genomic screen for post-transcriptional 5′ and 3′ regulatory elements
US6632800B1 (en) * 1999-08-17 2003-10-14 Mayo Foundation For Medical Education And Research System for monitoring the expression of transgenes
US6586411B1 (en) 2000-08-16 2003-07-01 Mayo Foundation For Medical Education And Research System for monitoring the location of transgenes
US7482425B2 (en) * 1999-08-26 2009-01-27 Amylin Pharmaceuticals, Inc. Compositions for lipid matrix-assisted chemical ligation
US6896881B1 (en) * 1999-09-24 2005-05-24 Mayo Foundation For Medical Education And Research Therapeutic methods and compositions using viruses of the recombinant paramyxoviridae family
HK1047109A1 (zh) * 1999-10-15 2003-02-07 University Of Massachusetts 作为指定基因干预工具的rna干预轨迹基因
US6867036B1 (en) 1999-11-23 2005-03-15 Mayo Foundation For Medical Education And Research Gene expression by positive feedback activation of a cell type-specific promoter
WO2001051183A1 (en) * 2000-01-07 2001-07-19 Proteros, Llc. Enhanced faraday cup for diagnostic measurements in an ion implanter
US7078171B2 (en) 2000-04-28 2006-07-18 Message Pharmaceutical, Inc. Methods for identifying novel nucleic acid regulatory elements and compounds that affect the regulation
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
EP1176196A1 (de) * 2000-07-24 2002-01-30 Message Pharmaceuticals, Inc. Funktionalle genomische Selektion für post-transkriptionale 5' und 3' Regulationselemente
KR100408844B1 (ko) * 2000-07-29 2003-12-06 한국산업기술평가원 동물세포 발현벡터
US7118740B1 (en) 2000-09-22 2006-10-10 Mayo Foundation For Medical Education And Research Method for limiting the growth of cancer cells using an attenuated measles virus
FR2815358A1 (fr) * 2000-10-17 2002-04-19 Parteurop Dev Polypeptides inhibiteurs de l'ires du virus de l'hepatite c et procede de criblage desdits polypeptides
US6420107B1 (en) * 2001-07-24 2002-07-16 University Of North Dakota Assay for identifying anti-viral agents specific for protein-coated double-stranded DNA viruses
DE10143106C1 (de) * 2001-09-03 2002-10-10 Artus Ges Fuer Molekularbiolog Vermehrung von Ribonukleinsäuren
AU2002341621A1 (en) * 2001-09-10 2003-03-24 Meso Scale Technologies, Llc Methods, reagents, kits and apparatus for protein function analysis
EP1435974A4 (de) * 2001-09-28 2006-09-06 Idenix Cayman Ltd Verfahren und zusamemnsetzungen zur behandlung des hepatitis-c-virus mit 4'-modifizierten nucleosiden
US7968086B2 (en) * 2001-11-26 2011-06-28 Duke University Genetically stable enterovirus expression vector with replaced stem loop VI
WO2003063888A1 (en) * 2002-01-30 2003-08-07 Robertson Hugh D Antiviral compositions and methods for identification and use
KR100425030B1 (ko) * 2002-02-01 2004-03-27 주식회사 이뮨메드 신규한 항바이러스 ｖｓｆ 단백질 및 이를 분비하는하이브리도마
US20030219723A1 (en) * 2002-05-20 2003-11-27 Lu Henry H. Compositions and methods for screening and identifying anti-HCV agents
EP1581628A4 (de) * 2002-09-13 2007-04-04 Smithkline Beecham Corp SATZ VON AM VIRALEN LEBENSZYKLUS BETEILIGTEN UBIQUITûREN ZELLPROTEINEN
US6821744B2 (en) 2002-10-29 2004-11-23 Roche Diagnostics Operations, Inc. Method, assay, and kit for quantifying HIV protease inhibitors
FR2848572B1 (fr) * 2002-12-12 2005-12-09 Univ Joseph Fourier Molecules inhibitrices de la synthese proteique du virus de l'hepatite c et procede de criblage desdites molecules inhibitrices
ATE554185T1 (de) * 2003-02-27 2012-05-15 Alnylam Pharmaceuticals Inc Verfahren und konstrukte zur bewertung von rnai- zielen und effektormolekülen
US20080311556A1 (en) * 2003-08-07 2008-12-18 Iversen Patrick L Sense Antiviral Compound and Method for Treating Ssrna Viral Infection
US20050164167A1 (en) * 2004-01-28 2005-07-28 Buscher Benjamin A. Method of discovery and development of broad-spectrum antiviral drugs
US8318423B2 (en) * 2004-07-06 2012-11-27 Focus Diagnostics, Inc. Methods and compositions for detecting rhinoviruses
TWI286574B (en) * 2004-07-27 2007-09-11 Univ Chung Yuan Christian Use of bicistronic DNA constructs for identifying compounds that inhibit IRES-dependent translation
US7588885B2 (en) * 2004-08-06 2009-09-15 Chung Yuan Christian University Use of biocistronic DNA constructs for identifying compounds that inhibit IRES-dependent translation
US8129352B2 (en) * 2004-09-16 2012-03-06 Avi Biopharma, Inc. Antisense antiviral compound and method for treating ssRNA viral infection
US8357664B2 (en) 2004-10-26 2013-01-22 Avi Biopharma, Inc. Antisense antiviral compound and method for treating influenza viral infection
US7524829B2 (en) * 2004-11-01 2009-04-28 Avi Biopharma, Inc. Antisense antiviral compounds and methods for treating a filovirus infection
WO2006121468A1 (en) * 2004-11-22 2006-11-16 Genelabs Technologies, Inc. 5-nitro-nucleoside compounds for treating viral infections
US20090111786A1 (en) * 2004-12-03 2009-04-30 Glass Christopher K Compounds that Prevent Macrophage Apoptosis and Uses Thereof
AR058419A1 (es) * 2005-02-28 2008-02-06 Gilead Sciences Inc Compuestos de nucleosidos triciclicos para tratar infecciones virales
DE202005004135U1 (de) * 2005-03-11 2005-05-19 Klocke Verpackungs-Service Gmbh Mehrkomponentenverpackung mit Applikator
US7405204B2 (en) * 2005-04-25 2008-07-29 Genelabs Technologies, Inc. Nucleoside compounds for treating viral infections
CN101223161A (zh) * 2005-06-24 2008-07-16 健亚生物科技公司 治疗病毒感染的杂芳基衍生物
US8524676B2 (en) * 2005-09-08 2013-09-03 Sarepta Therapeutics, Inc. Method for treating enterovirus or rhinovirus infection using antisense antiviral compounds
WO2007030576A2 (en) * 2005-09-08 2007-03-15 Avi Biopharma, Inc. Antisense antiviral compound and method for treating picornavirus infection
US8501704B2 (en) 2005-11-08 2013-08-06 Sarepta Therapeutics, Inc. Immunosuppression compound and treatment method
RU2008128453A (ru) 2005-12-12 2010-01-20 Дженелабс Текнолоджис, Инк. (Us) Соединение n-(5-членных арил)-амидов, фармацевтическая композиция с противовирусной активностью на их основе, способ лечения или профилактики вирусной инфекции с их помощью и способ их получения
CA2633541A1 (en) * 2005-12-12 2007-06-21 Genelabs Technologies, Inc. N-(6-membered aromatic ring)-amido anti-viral compounds
US8785407B2 (en) * 2006-05-10 2014-07-22 Sarepta Therapeutics, Inc. Antisense antiviral agent and method for treating ssRNA viral infection
CN101356652B (zh) * 2006-06-02 2012-04-18 日本财团法人高知县产业振兴中心 包括由氧化锌构成的氧化物半导体薄膜层的半导体器件及其制造方法
BRPI0714299A2 (pt) * 2006-07-20 2013-04-24 Genelabs Tech Inc inibidores virais policÍclicos
US7598040B2 (en) * 2006-11-22 2009-10-06 Trana Discovery, Inc. Compositions and methods for the identification of inhibitors of protein synthesis
KR20090114430A (ko) 2007-02-02 2009-11-03 베일러 리서치 인스티튜트 항원-제시 세포 상에서 발현된 ｄｃｉｒ에 대한 항원 표적화에 기초한 백신
TWI422594B (zh) * 2007-02-02 2014-01-11 Baylor Res Inst 經由樹狀細胞去唾液酸糖蛋白受體（ｄｃ-ａｓｇｐｒ）接合抗原呈現細胞之藥劑
CA2695989A1 (en) * 2007-08-10 2009-02-19 Glaxosmithkline Llc Certain nitrogen containing bicyclic chemical entities for treating viral infections
WO2009029729A1 (en) * 2007-08-31 2009-03-05 Genelabs Technologies, Inc. Amino tricyclic-nucleoside compounds, compositions, and methods of use
EP2201118B1 (de) * 2007-09-14 2012-04-18 Trana Discovery Zusammensetzungen und verfahren zur identifizierung von inhibitoren einer retrovirusinfektion
US8695094B2 (en) * 2008-06-24 2014-04-08 International Business Machines Corporation Detecting secondary infections in virus scanning
EP2342339A4 (de) * 2008-09-29 2012-06-06 Trana Discovery Inc Screening-verfahren zur identifizierung spezifischer staphylococcus aureus-inhibitoren
US20100204265A1 (en) * 2009-02-09 2010-08-12 Genelabs Technologies, Inc. Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections
US9052304B2 (en) 2009-03-13 2015-06-09 Terrasep, Llc Methods and apparatus for centrifugal liquid chromatography
EP2499248B1 (de) 2009-11-13 2017-01-04 Sarepta Therapeutics, Inc. Antivirale antisense-verbindung und verfahren zur behandlung von influenzavirusinfektion
AR082453A1 (es) 2010-04-21 2012-12-12 Novartis Ag Compuestos de furopiridina, composiciones farmaceuticas que los contienen y usos de los mismos
MX2012015097A (es) 2010-07-02 2013-05-28 Gilead Sciences Inc Derivados de acido naft-2-ilacetico para tratar sida.
EP2588455B1 (de) 2010-07-02 2018-04-04 Gilead Sciences, Inc. 2-quinolinyl-essigsäure derivate als hiv antivirale verbindungen
MA34462B1 (fr) 2010-07-22 2013-08-01 Novartis Ag Composes de thiophene 2,3,5- trisubstitues et leurs utilisations
US8198429B2 (en) 2010-08-09 2012-06-12 Avi Biopharma, Inc. Antisense antiviral compounds and methods for treating a filovirus infection
US9951117B2 (en) 2010-09-02 2018-04-24 Mayo Foundation For Medical Education And Research Vesicular stomatitis viruses
WO2012031137A2 (en) 2010-09-02 2012-03-08 Mayo Foundation For Medical Education And Research Vesicular stomatitis viruses
EP2658857B1 (de) 2010-12-29 2016-11-02 Inhibitex, Inc. Substituierte purin-nukleoside, phosphoroamidate und phosphorodiamidatderivate zur behandlung von virusinfektionen
UA111841C2 (uk) 2011-04-21 2016-06-24 Гіліад Сайєнсіз, Інк. Сполуки бензотіазолу та їх фармацевтичне застосування
US9376392B2 (en) 2012-01-04 2016-06-28 Gilead Sciences, Inc. 2-(tert-butoxy)-2-(7-methylquinolin-6-yl) acetic acid derivatives for treating AIDS
US9284323B2 (en) 2012-01-04 2016-03-15 Gilead Sciences, Inc. Naphthalene acetic acid derivatives against HIV infection
UY34750A (es) 2012-04-20 2013-11-29 Gilead Sciences Inc ?compuestos para el tratamiento del hiv, composiciones,métodos de preparación, intermediarios y métodos terapéuticos?.
TWI448538B (zh) 2012-10-23 2014-08-11 Ind Tech Res Inst 螢光材料與紫外光發光裝置
WO2015175957A1 (en) 2014-05-16 2015-11-19 Baylor Research Institute Methods and compositions for treating autoimmune and inflammatory conditions
EP3292215A1 (de) * 2015-05-06 2018-03-14 The Procter and Gamble Company Entgiftung von mikrobiellen virulenzfaktoren in der mundhöhle
GB202016650D0 (en) * 2020-10-20 2020-12-02 Primer Design Ltd Kit and method

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3280400D1 (de) * 1981-10-23 1992-06-04 Molecular Biosystems Inc Oligonukleotides heilmittel und dessen herstellungsverfahren.
GB8911555D0 (en) * 1989-05-19 1989-07-05 Inglis Stephen C Ribosomal frame-shift signals and uses
ES2104717T3 (es) * 1990-08-16 1997-10-16 Isis Pharmaceuticals Inc Oligonucleotidos para modular los efectos de las infecciones por citomegalovirus.
ATE213779T1 (de) * 1991-08-07 2002-03-15 W French Anderson Interne ribosom eintrittsstellen enthaltene retrovirale vektoren

Also Published As

Publication number Publication date
AU6497694A (en) 1994-10-24
JPH08509213A (ja) 1996-10-01
DE69434931D1 (de) 2007-04-12
US6156496A (en) 2000-12-05
CA2159639A1 (en) 1994-10-13
EP0693126B1 (de) 2007-02-28
EP0693126A1 (de) 1996-01-24
JP3901726B2 (ja) 2007-04-04
WO1994023041A3 (en) 1995-01-05
HK1009980A1 (en) 1999-06-11
US5738985A (en) 1998-04-14
EP0693126B9 (de) 2007-09-12
JP2007075116A (ja) 2007-03-29
WO1994023041A2 (en) 1994-10-13
DE69434931T2 (de) 2007-11-22

Similar Documents

Publication Publication Date Title
ATE355380T1 (de) Methode zur selektiven inaktivierung der viralen replication
DK0891420T3 (da) Fremgangsmåde til replikation af influenzavirus i cellekultur samt de ved fremgangsmåden opnåelige influenzavirus
DE60035032D1 (de) Verwendung von pioglitazone zur verbesserung der ketose und der azidose
EA199801031A1 (ru) Ингибиторы протеинфарнезилтрансферазы
WO2005042767A3 (en) Compositions and methods for detecting severe acute respiratory syndrome coronavirus
DK0904351T3 (da) Dyreceller og fremgangsmåder til replikationen af influenzavirus
SE8405133L (sv) Anti-viralt medel
BR0212469A (pt) Método para multiplicação de vìrus em cultura de célula
EA200500584A1 (ru) Нуклеозидные производные для лечения инфекционных заболеваний, вызванных вирусом гепатита c
PT842276E (pt) Metodo para a reproducao in vitro das actividades de rna polimerase dependente de rna e nucleotidil-transferase terminal codificadas pelo virus da hepatite c (hcv)
ES2018648B3 (es) Metodo para la deteccion de proteinas y virus.
DE69128077D1 (de) Nuklein-säure amplifikation mit dns abhängigen rns polymerasen aktivität von rns-replikasen
PT698216E (pt) Metodos de tipificacao do virus da hepatite c e reagentes para utilizar nestes
AR071880A2 (es) Metodo para marcar de forma detectable pestivirus
DK0713495T3 (da) Fremgangsmåder til forstærkning af den biologiske aktivitet af chemokiner
ES2175462T3 (es) Composiciones cristalizables que comprenden un complejo del dominio de proteasa ns3 del virus de la hepatitis c/ns4a, y cristales asi obtenidos.
DK0832211T3 (da) Oligonucleotider, der er specifikke for hepatitis B-virus.
ES2123048T3 (es) Analogos de nucleosidos antiviricos.
DE58904809D1 (de) Plasma-roentgenroehre, insbesondere zur roentgen-vorionisierung von gaslasern, und verwendung als elektronenkanone.
FI880960L (fi) Anvaendning av rnas l inhibitor som markeringsaemne i virusinfektioner.
EP0914422A4 (de) Säugetiergene, die an viraler infektion und tumorunterdrückung beteiligt sind
ATE255594T1 (de) Hepatitis b inhibitoren
DE69705583D1 (de) Antivirusverbindungen
DE60117561D1 (de) Verbesserte replikation von hcv rna
AU2003302275A1 (en) Bicyclic carbohydrate compounds useful in the treatment of infections caused by flaviviridae sp., such as hepatitis c and bovine viral diarrhea viruses

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties